Startup profile for MegaRobo Technologies: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

MegaRobo Technologies funding, valuation and investors

Suzhou-based robotics and AI-for-science infrastructure developer; announced nearly $200M of new financing November 18, 2026.

Verified company research · funding, investors and latest developments

Keep track of MegaRobo Technologies

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Financing (series undisclosed; near amount)

Nearly $200M (exact amount undisclosed) · November 18, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$200M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · Suzhou, China

Investors in latest funding

Other: Oman Investment Authority , CMB International , Asia Investment Capital , Granite Asia , Sinovation Ventures

Sources: latest funding · prnewswire.com Last verified: 2026-11-19

Overview

MegaRobo Technologies builds robotics, scientific-laboratory automation and an AI for Science software-hardware stack. The Chinese company's November 18, 2026 20:39 ET issuer release reports 'nearly $200 million' of financing joined by Oman Investment Authority, CMB International and existing Asia Investment Capital, Granite Asia and Sinovation Ventures.

No exact financing size, round series, valuation, ownership percentages or lead investor are disclosed. The vendor claims products deployed to more than 500 institutional/industry customers and over 200 Megalaxy Lab users; these are company claims, not independent sales, customer retention or scientific performance audits.

Why MegaRobo Technologies is interesting

MegaRobo's company-issued late-November 18 release says it secured nearly $200M, but NOT an exact $200M amount or named lead. Its One Intelligence Stack aims to connect lab instruments and experiments to AI agents, creating a physical feedback loop with 500+ company-reported customers. Distinguish deployed lab automation from speculative fully autonomous scientific discoveries.

Product & use cases

Illustrative institutional laboratory workflow: configure scientific experiment goals and instrument constraints; connect compatible robots, liquid handlers and lab management software; orchestrate automated experimental tasks with human safety oversight; collect instrument readings and provenance in structured formats; feed results into AI model evaluation and next-experiment proposals. MegaRobo markets 'One Intelligence Stack' and Megalaxy Lab for this loop, but compatibility, autonomous scope, integration labor, pricing and scientific outcome reproducibility must be validated in procurement.

  • Automate sample handling and experiment execution in life-sciences R&D labs
  • Collect structured experiment data for iterative AI model workflows
  • Manage scientific instrument and robotics workflows through software

Key facts

  • November 18 late ET: company-issued release reports nearly $200M financing, exact amount and stage undisclosed.
  • Participants: Oman Investment Authority, CMB International, existing Granite Asia, Sinovation Ventures and Asia Investment Capital; no lead formally disclosed.
  • Vendor-reported 500+ customers and 200+ Megalaxy Lab users; not audited revenue or trial results.
  • AI-for-science uses real experimental robotics; advanced autonomy and scientific discoveries require external validation.

Funding history (newest first)

Financing (series undisclosed; near amount)

2026-11-18 Nearly $200M (exact amount undisclosed)
  • Oman Investment Authority (participant)
  • CMB International (participant)
  • Asia Investment Capital (participant)
  • Granite Asia (participant)
  • Sinovation Ventures (participant)

Source: Read source · prnewswire.com

Competitive landscape

Edge: Positions integrated laboratory robotics, automated execution and AI/data as one workflow rather than only laboratory informatics; procurement advantage remains unproven without quantified operating outcomes.

The strongest financial question is whether physical integration, utilization and recurring software spending create sustainable margins, not a claim that AI has independently 'discovered' new drugs. The issuer says more than 500 customers and >200 Megalaxy Lab users; its current website uses a broader 880+ clients figure of potentially different scope/date, so do not imply strictly comparable datasets or independent validation.

  • Emerald Cloud Lab direct

    Remote automated lab execution; compare actual experiments supported and cost.

  • Strateos direct

    Cloud laboratory workflows and experiment automation, especially life-sciences R&D.

  • Automata direct

    Laboratory robotics and automation hardware/platform.

  • Synthace adjacent

    Software to design, automate and analyze lab experiments; robotics coverage differs.

  • Benchling adjacent

    R&D informatics and data system; physical execution requires lab interfaces.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about MegaRobo Technologies

Practical answers founders, operators, and investors typically search for.

No. The issuer describes the round as 'nearly $200 million'. It does not disclose an exact amount or formal financing series.
The issuer lists Oman Investment Authority, CMB International and returning investors, but does not formally name a lead.
Laboratory automation and robotics, with software/AI tooling for scientific experiment execution and data. Pricing, project margins and verified results were not publicly disclosed.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.